Paper41589205
Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma.
Bisht S and 2 others. Hepatol Forum, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma. Papers, record 41589205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41589205
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References105
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33322337 | Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33322337 | PubMed |
| 2 | 36831004 | Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. | Biomedicines | 2023 | https://conductscience.org/library/papers/36831004 | PubMed |
| 3 | 38069291 | Role of the Insulin-like Growth Factor (IGF) Axis in Diseases. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38069291 | PubMed |
| 4 | 34916492 | Targeting PI3K/Akt signal transduction for cancer therapy. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34916492 | PubMed |
| 5 | 39981963 | Serum Insulin-Like Growth Factor 1 and the Prognosis of Patients With Advanced Liver Diseases: A Meta-Analysis. | Clin Transl Gastroenterol | 2025 | https://conductscience.org/library/papers/39981963 | PubMed |
| 6 | 29535161 | IGF1 receptor signaling pathways. | J Mol Endocrinol | 2018 | https://conductscience.org/library/papers/29535161 | PubMed |
| 7 | 38539547 | Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38539547 | PubMed |
| 8 | 39592715 | Epigenetic dysregulation of H19/IGF2 in hepatic cells exposed to toxic metal mixtures in vitro. | Sci Rep | 2024 | https://conductscience.org/library/papers/39592715 | PubMed |
| 9 | 38392069 | Insulin Resistance: The Increased Risk of Cancers. | Curr Oncol | 2024 | https://conductscience.org/library/papers/38392069 | PubMed |
| 10 | 36533882 | Cancer of the Liver and its Relationship with Diabetes mellitus. | Technol Cancer Res Treat | 2022 | https://conductscience.org/library/papers/36533882 | PubMed |
| 11 | 39138146 | Therapeutic advances of targeting receptor tyrosine kinases in cancer. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138146 | PubMed |
| 12 | 33330100 | Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. | Front Oncol | 2020 | https://conductscience.org/library/papers/33330100 | PubMed |
| 13 | 38105263 | Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38105263 | PubMed |
| 14 | 37834331 | The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834331 | PubMed |
| 15 | 32493414 | Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32493414 | PubMed |
| 16 | 22234739 | Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). | Ann Oncol | 2012 | https://conductscience.org/library/papers/22234739 | PubMed |
| 17 | 38523466 | Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. | J Liver Cancer | 2024 | https://conductscience.org/library/papers/38523466 | PubMed |
| 18 | 36254201 | Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2022 | https://conductscience.org/library/papers/36254201 | PubMed |
| 19 | 36763374 | Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies. | Oncologist | 2023 | https://conductscience.org/library/papers/36763374 | PubMed |
| 20 | 32415542 | The Actions of IGF-1 in the Growth Plate and Its Role in Postnatal Bone Elongation. | Curr Osteoporos Rep | 2020 | https://conductscience.org/library/papers/32415542 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42572789 | A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM). | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42572789 | PubMed |
| 42554920 | Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications. | Curr Obes Rep | 2026 | https://conductscience.org/library/papers/42554920 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| IGF1 | 3479 | PubTator's text mining | https://conductscience.org/library/genes/3479 | NCBI Gene |
| IGF1R | 3480 | PubTator's text mining | https://conductscience.org/library/genes/3480 | NCBI Gene |
| IGF2 | 3481 | PubTator's text mining | https://conductscience.org/library/genes/3481 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41589205
GET https://conductscience.org/api/papers/v1/41589205/references?page=2